LevelStock.com: ImmunoCellular TherapeuticsaEUR(TM) Chief Scientific Officer Authors Text on Cancer Stem Cell Research

ImmunoCellular Therapeutics (OTCBB: IMUC) announced today that John S. Yu, M.D., the company's Chief Scientific Officer and Chairman of the Board, has helped publish a new scientific text entitled Cancer Stem Cells: Methods and Protocols, published by Humana Press. Dr. Yu, a Harvard-educated and Massachusetts General Hospital-trained physician-scientist who has received numerous awards for his work in neurological studies, was the editor for the book, which takes a look at the role of stems cells in cancer initiation and propagation. The book covers a host of topics related to cancer stem cell research techniques and protocols, and is part of Humana Press' highly successful series Methods in Molecular Biology, which focuses on biomedical and life science research methods and protocols.

About ImmunoCellular Therapeutics, Ltd.

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently completed a Phase I trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. The Company is planning to initiate a multicenter phase II study in the second half of 2010. The Company's "off the shelf" therapeutic vaccine product candidate (ICT-121) targeting cancer stem cells for multiple cancer indications is targeted by IMUC to enter clinical trials for glioblastoma during the second half of 2010. IMUC has entered into a research and license option deal with the Roche Group for one of the Company's monoclonal antibody product candidates for the diagnosis and treatment of ovarian cancer and multiple myeloma, which provides for potential licensing and milestone payments of $32MM and royalties if the Roche Group exercises its option and commercializes this antibody technology for multiple indications. IMUC is in pre-clinical development of another monoclonal antibody product candidate for the treatment of small cell lung cancer and pancreatic cancer, and is also evaluating its platform technology for monoclonal antibody discovery to target cancer stem cells. To learn more about IMUC, please visit www.imuc.com.

Forward-Looking Statements

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including without limitation, the risks associated with the potential inability to obtain licenses from third parties that will be needed to commercialize ICT-107 in many major commercial territories; the potential inability to secure a partner to fund development and marketing of ICT-107; the risk that future trials of ICT-107, if any, do not confirm the safety and efficacy data generated in the Phase I trial; the need to satisfy performance milestones to maintain the vaccine technology licenses with Cedars-Sinai; the risks associated with obtaining a patent that provides commercially significant protection for ICT-107; the risk of encountering substantial delays in completing or being unable to successfully complete the pre-clinical testing necessary before initiating clinical testing of ICT-121; and the need for substantial additional capital to fund development of product candidates beyond their initial clinical or pre-clinical stages and to continue IMUC's operations. Additional risks and uncertainties are described in IMUC's most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K. IMUC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

About LevelStock.com

We are an investor community and investors relations website specializing in emerging growth stocks in today's Hot Sectors and providing a platform of services for SmallCap, MicroCap, NanoCap Companies.

We encourage everyone to join our social media sites:

Free Subscription For Our Newsletters: http://www.levelstock.com/

FaceBook: http://www.facebook.com/group.php?gid=283660480870

Twitter: http://twitter.com/levelstock

LevelStock.com is not a registered investment advisor or broker-dealer. The information here is believed to be reliable, but not guaranteed to be accurate by LevelStock.com Please be advised that the information contained may or may not be complete and is solely for informational purposes only. Please read our full disclaimer for complete risks and disclosures http://levelstock.com/news.php?viewStory=19

CONTACT: LevelStock.com e-mail: support@levelstock.com